Background: Intensification of pharmacotherapy in persons with poorly controlled chronic conditions has been proposed as a clinically meaningful process measure of quality. Objective: To validate measures of treatment intensification by evaluating their associations with subsequent control in hypertension, hyperlipidemia, and diabetes mellitus across 35 medical facility populations in Kaiser Permanente, Northern California. Design: Hierarchical analyses of associations of improvements in facility-level treatment intensification rates from 2001 to 2003 with patient-level risk factor levels at the end of 2003. Patients: Members (515,072 and 626,130; age Ͼ20 years) with hypertension, hyperlipidemia, and/or diabetes mellitus in 2001 and 2003, respectively. Measurements: Treatment intensification for each risk factor defined as an increase in number of drug classes prescribed, of dosage for at least 1 drug, or switching to a drug from another class within 3 months of observed poor risk factor control. Results: Facility-level improvements in treatment intensification rates between 2001 and 2003 were strongly associated with greater likelihood of being in control at the end of 2003 (P Յ 0.05 for each risk factor) after adjustment for patient-and facility-level covariates. Compared with facility rankings based solely on control, addition of percentages of poorly controlled patients who received treatment intensification changed 2003 rankings substantially: 14%, 51%, and 29% of the facilities changed ranks by 5 or more positions for hypertension, hyperlipidemia, and diabetes, respectively.
M orbidity and mortality from cardiovascular diseases are largely attributable to poor control of hypertension, hyperlipidemia, and diabetes mellitus, along with cigarette smoking. [1] [2] [3] [4] [5] Despite the availability of evidence-based treatments, 6 -10 recent reports [11] [12] [13] [14] find persistent suboptimal control of blood pressure, low-density lipoprotein (LDL)-cholesterol and hemoglobin A1c. Moreover, physicians often fail to intensify pharmacologic treatment appropriately in the face of poor risk factor control. [15] [16] [17] [18] [19] [20] [21] "Clinical inertia" has been suggested as an explanation for poor control and a target for quality improvement. 15, 22, 23 Kerr et al 24, 25 and others 15 have suggested that measurement and feedback of the frequency with which pharmacotherapy is intensified in patients with poorly controlled risk factors may represent a useful approach to clinical quality measurement and improvement. Voorham et al 26 found that simple measures of proportions of patients in control for hypertension, hyperlipidemia, and diabetes underestimate the proportions receiving high quality clinical care and concluded that more sophisticated measures including measures of treatment intensification could improve quality assessment. Considering a process measure such as treatment intensification along with measures of risk factor control addresses concerns that case-mix differences rather than variation in clinical quality could explain observed differences in control and may reduce provider reluctance to include difficult-to-treat patients in their panels. It may also reduce risks of overtreatment and adverse consequences from an overzealous focus on tight risk factor targets. 27, 28 Because numerous clinical trials demonstrate that treatment intensification leads to improved hypertension, hyperlipidemia, and diabetes control, intensification measures have been called "tightly linked" 24, 25 or "evidence-based," in contrast to simpler nonevidence-based processes such as rates of testing.
However, linkage of treatment intensification rates in populations, as would be used in quality measurement, with better rates of risk factor control has not yet been demonstrated.
We reported treatment intensification rates 29 in patients with poorly controlled hypertension, hyperlipidemia, or diabetes mellitus for Kaiser Permanente Northern California during 2003. Intensification rates were somewhat higher than in earlier reports, 15, 18, 19 but room for further improvement remained and significant variation in rates was observed across the 39 medical facilities within this system. In this paper, we test hypotheses that variation among these facilities in treatment intensification rates for hypertension, hyperlipidemia, and diabetes mellitus are associated with differences in levels of risk factor control.
METHODS

Study Population
The study population has been described previously. 29, 30 We identified all adult members (age Ն20 years) of Kaiser Permanente Northern California who were recognized by clinicians as having hypertension, diabetes mellitus, and/or hyperlipidemia during 2 18-month periods (July 1, 2000 -December 31, 2001 and July 1, 2002 -December 31, 2003 , and were continuously enrolled for at least the final 4 months of either period. Kaiser Permanente is an integrated health care system providing comprehensive care to a diverse population 31 of approximately 3.2 million members in Northern California.
Identifying criteria for each condition are given in Appendix 1, Supplemental Digital Content, http://links.lww. com/A739. Patients with elevated risk factor values were not included if no evidence was found of physician awareness (ie, recorded diagnoses, prescriptions for disease-specific medications, or in the case of diabetes a follow-up hemoglobin A1c test). Cutpoints for identifying hyperlipidemia varied depending on patients' cardiovascular disease risk status, using ATP-III guidelines. 7 Assignment of risk required identification of previous coronary heart disease from inpatient and outpatient diagnoses and calculation of 10-year coronary heart disease risk for each patient. Totals of 515,072 and 626,130 members met criteria for hypertension, hyperlipidemia, and/or diabetes in 2001 and 2003, respectively. Enrollment and demographic data (age, sex) were obtained from membership databases. Burden of comorbid illness was assessed using the DxCG Diagnostic Cost Group risk adjustment methodology, 32, 33 which is based on 1-year hospital discharge and ambulatory diagnoses (for 2003). Self-reported race/ethnicity was found for approximately 88% of all members using information from birth, maternity, and hospitalization records and responses to member satisfaction surveys.
Members were assigned to a facility using the location of their primary care provider, as recorded in system databases. We excluded 20,134 (3%) otherwise eligible patients from 4 small facilities that opened after the end of 2001, because change scores could not be calculated for these facilities, and an additional 2.5% of eligible patients who could not be linked with a primary care provider.
Definitions of Control
Risk factor control was assessed for all patients with each condition, based on last recorded values in 2001 and 2003 from laboratory (LDL-cholesterol and hemoglobin A1c) and encounter (blood pressure) databases. We have previously shown that last readings are equivalent to means of all readings within a year for aggregate measures. 34 Values were available for at least 95% of those with hypertension and for 94% of those with hyperlipidemia or diabetes in each year. Persons with no values for a condition were excluded only from analyses of that condition.
For each condition, we defined 2 levels of control ( Table 1) . "Stringent control" was defined using the most rigorous guideline targets in place in 2003. "Near control" was then defined using somewhat higher cutpoints that corresponded with the action levels used in calculating treatment intensification (see below). "Poor control" designates values above the cutpoints for near control. Definitions of control also varied depending on risk for both LDL-cholesterol and blood pressure ( Table 1 ). In December 2002, a switch to the IFCC reference standard promoted by the National Glycohemoglobin Standardization Group 35 at Kaiser Permanente's regional laboratory effected an immediate decrease of 0.3 percentage points in Hb A1c values. This affected all facilities simultaneously, but led to a prompt 10%-point improvement in the percentage of patients with A1c values Ͻ7%. 
Treatment Intensification
Treatment intensification was identified from pharmacy databases and calculated for all patients who met criteria for poor control at any point during either year. We did not measure intensification for those in near control out of concern that an intensification measure in these patients could encourage overtreatment and adverse effects. Intensification was defined as an increase in number of drug classes prescribed, increased dosage of at least 1 medication, or a switch to another medication in a different therapeutic class within 3 months (and 6 months) following the initial observation of poor control. Follow-up was extended into 2004 to detect intensification when poor control was first identified in the last months of 2003.
Seven medication classes were tabulated for hypertension, 5 for hyperlipidemia and 5 for diabetes. 29 Daily dosages were categorized as low, medium, or high based on package insert recommendations and inspection of actual dosage distributions. Dosages at or below recommended initial starting doses were categorized as low; those within the recommended maintenance range as intermediate; and dosages at or above the high end of the recommended range as high. To identify intensification, comparison was made to medications dispensed during the 4-month period before poor control was noted. We included switches to a medication in a different class as treatment intensifications because they represent physician responses intended to render therapy more "intense" either by changing to a more effective or better tolerated medication. Only 11%, 2%, and 4% of "intensifications" for hypertension, hyperlipidemia, and diabetes were solely switches among classes. We excluded all patients with diabetes who were using insulin before the observation of poor control because day-to-day adjustments in insulin can not be identified in prescription databases.
Data Analyses
We examined whether longitudinal improvements in treatment intensification were associated with improvements in control for each condition. Primary analyses treated both stringent and near control as being in control, because these were the cutpoints used in calculating treatment intensification. However, we repeated all analyses to see whether treatment intensification as calculated was also associated with rates of stringent control.
We examined interfacility differences in proportions of patients in stringent and stringent/near control and proportions of poorly controlled patients receiving treatment intensification for each time period and condition. Systolic rather than diastolic blood pressure control was examined because of its greater importance in predicting coronary heart disease risk. 36, 37 Only 19% of all hypertensive patients had diastolic pressure Ն90 mmHg in 2003 and of these, 85% of those also had elevated systolic pressure.
Unadjusted associations of facility-level improvements in treatment intensification with improvements in control rates from 2001 to 2003 were assessed using Spearman rank correlations. To adjust for case-mix differences and baseline differences in control, we constructed hierarchical logistic regression models for each condition. Models were fit to data with 1 record for each patient who was in the study population in 2003. Dependent variables were dichotomous indicators of whether the patient was in control (stringent/near control vs. poor control) for the condition at the end of 2003. Each model included 3 fixed effects at the facility-level, 6 fixed effects at the patient-level, a random-effect for facilities, and a random-effect for physicians nested within facilities. One of the facility-level predictors, improvement in a facility's treatment intensification rates from 2001 to 2003, was the main effect in each model. The facility-level covariates included the percent of patients in control in 2001 and the percent of poorly controlled patients receiving treatment intensification in 2001. Patient-level covariates included age, sex, race-ethnicity, the Diagnostic Cost Group score, and presence of either or both of the other 2 conditions. Race-ethnicity was included because African American patients are consistently found to have higher levels and more difficulty controlling each of these risk factors. [38] [39] [40] Raceethnicity distributions differed greatly by facility and treatment intensification has been previously shown to vary by race/ ethnicity. 29 Hyperlipidemia models were further adjusted for patients' prior history of coronary heart disease and hypertension models for prior history of target organ disease as defined by JNC VI, 41 because these characteristics altered target LDLcholesterol 7 and blood pressure levels 40 in place during this period, may have differed between facilities, and therefore could confound facility comparisons of treatment intensification and control. We used Generalized Linear Models ͓SAS PROC MIXED with GLIMMIX Macro (Version 9.1)͔ to adjust for unmeasured covariates that may cluster by facility or provider.
Model results are presented as adjusted odds ratios for control associated with a 1 percentage point change in the facility treatment intensification rates from 2001 to 2003. To facilitate interpretation of these results, we used all model coefficients to calculate predicted probabilities of being in control at 2 different facilities: 1 with the average observed improvement in treatment intensification and the other with 5 percentage points greater improvement. This 5% difference represents one third to one half of the observed ranges across facilities for increases in treatment intensification for the 3 risk factors. The predicted differences in control (and 95% confidence intervals) are presented.
In sensitivity analyses, we examined associations of treatment intensification with likelihood of being in stringent control (rather than in stringent/near control). We also refit models after deleting small percentages whose only treatment intensification was switching to a medication of a different class; and after lengthening the period in which treatment intensification could occur to 6 months.
To study the impact of measuring treatment intensification on performance ranking, we compared crude rankings of the 35 facilities by proportions in control (stringent or near control) at the end of 2003 with rankings based on combined measures of proportions in control or receiving treatment intensification. Patients who received treatment intensification during the year and were in control by their last reading were counted as in control, not as having received treatment intensification. We calculated the mean change in rankings and the proportion of facilities that changed by 5 or more rank Table 2) , especially for hyperlipidemia, but there were no important changes in age, gender, or race distributions, nor in disease severity for hypertension or hyperlipidemia. Sample sizes per facility were large, the smallest cell being 240 diabetic patients at 1 facility in 2001. Proportions of patients who were African American varied widely across facilities as did mean age and levels of comorbidities.
RESULTS
Numbers of persons meeting criteria for each condition increased between 2001 and 2003 (
Levels of Control and Treatment Intensification
Control improved for each condition from 2001 to 2003 (Table 2 ) and varied substantially across facilities in both years. For hypertensive patients, 48% and 78% met criteria for stringent control and stringent/near control of systolic blood pressure, respectively, in 2003; 45% and 77% of those with hyperlipidemia met these criteria for LDL-cholesterol; and 51% and 77% of diabetic patients did so for hemoglobin A1c. Improvements in control appeared greatest for hemoglobin A1c, but as much as half of this was due to the change in laboratory standardization.
On average, treatment intensification for hypertension increased by 7 percentage points from 2001 to 2003; increases were smaller for hyperlipidemia and diabetes. These changes varied from less than 1% to a 15.2% increase for hypertension, from a 9% decrease to a 9.4% increase for hyperlipidemia, and from a 4.9% decrease to 7.4% increase for diabetes.
Association of Treatment Intensification With Control
Facility-level increases in treatment intensification from 2001 to 2003 were associated with concurrent improvements in control rates (stringent/near control) for each condition (Spearman rank correlations: 0.47, P ϭ 0.004 for hypertension; 0.49, P ϭ 0.003 for hyperlipidemia; 0.34, P ϭ 0.05 for diabetes) (see Figs. 1A-C, Supplemental Digital Content, http://links.lww.com/A739). Correlations with improvements in stringent control were of similar size for hypertension and hyperlipidemia, but somewhat weaker for diabetes (Spearman rank correlation: 0.20, P ϭ 0.24 for diabetes).
In hierarchical models, improvement in a facility's treatment intensification rate from 2001 to 2003 was positively associated with a patient's likelihood of being in control (stringent/near control) at the end of 2003 (P Ͻ 0.05 for each condition) after adjustment for facility-and patient-level covariates (Table 3) . Compared with the average improvement, a 5% greater increase in the facility's treatment intensification rate predicted a 1.1% greater likelihood of systolic blood pressure control; a 1.0% greater likelihood of LDL-cholesterol control; and a 1.9% greater likelihood of hemoglobin A1c control. These associations are remarkably strong considering that only 23% to 25% of patients were eligible for treatment intensification, while control was measured in the entire affected population. Higher facility-level control and treatment intensification rates in 2001 were also strong, independent predictors of patient control in 2003.
Associations were of similar size when the dependent variables were changed to being in stringent control (adjusted OR's: systolic blood pressure: 1.012, P ϭ 0.01; LDL-cholesterol: 1.013, P ϭ 0.018; and hemoglobin A1c, 1.020, P ϭ 0.0005); when switching to a medication in a different class was not counted as treatment intensification; and when the period for identifying treatment intensification was lengthened to 6 months.
Among patient-level predictors, greater age was associated with poorer control of systolic blood pressure but better control for LDL-cholesterol and hemoglobin A1c. Female gender was associated with slightly lower odds of blood pressure and LDL-cholesterol control, but not with hemoglobin A1 control. Compared with white patients, all nonwhite race/ethnicity groups were substantially less likely to be in control for A1c values. African and Native-Americans were also less likely to be in control for hypertension and hyperlipidemia, but Asian patients were more likely to be in control for each. Greater levels of comorbidity were associated with better blood pressure control, but not with better LDL-cholesterol or hemoglobin A1c control.
Comparison of Rankings
In comparisons of facility rankings based on proportions in control with proportions in control or receiving treatment intensification, Spearman correlations were highest, and changes in rank least for hypertension, greatest for hyperlipidemia, and intermediate for diabetes (Table 4 ). Fourteen percent, 51%, and 29% of the facilities changed ranks by 5 or more positions for hypertension, hyperlipidemia, and diabetes, respectively (more detail is available in Figs 
DISCUSSION
Clinical inertia remains an important cause of poor risk factor control in chronic conditions. 20, 21 Clinical uncertainty and competing demands contribute to inertia. 42 Nevertheless, the present findings confirm that clinical populations experiencing greater increases in treatment intensification rates for hypertension, hyperlipidemia, and diabetes mellitus had better control of these conditions, strengthening the case that greater emphasis on treatment intensification would be useful for quality improvement. 24 -26 The strength of the associations we observed was large for each condition. Five percent improvements in treatment intensification, calculated in the 32% to 38% of patients eligible for intensification, led to 1.0% to 1.9% improvements in control for the entire population. Associations were equally strong whether we used less stringent or stricter definitions of control. We related an aggregate (facility-level) measure of improvements in treatment intensification to patient level control for 2 reasons. First, it was the population measure of treatment intensification that we wished to validate. Although many clinical trials demonstrate that addition or dosage increases of these medications lowers risk factor levels in individuals, it could still be argued that when treatment intensification is aggregated to the population level, higher rates may not necessarily be equivalent to better control. Conceivably, the wrong patients could be intensified or the wrong medications used. Nonadherence to medications could undermine effects of intensification. The present analyses reduce these concerns and suggest that, on average, physicians groups or health plans with higher intensification rates for these conditions are achieving better control.
Second, using this aggregate or "grouped treatment" approach is less biased than individual-level observational studies by confounding by indication. [43] [44] [45] Thus, in a recent observational study, 46 individual patients with poorly controlled hypertension who received treatment intensification appeared more likely to remain poorly controlled than those who did not. In a second study, 21 only a weak, nonsignificant association of treatment intensification with better hypertension control was found, even after controlling for baseline blood pressure levels. In each case, physician decisions to preferentially intensify treatment in those patients with higher baseline levels or known difficulties in control obscured the real benefits of intensification. By focusing on practice variation between facilities rather than between patients, we reduce such confounding.
More generally, our findings support the concept that tightly-linked or evidence-based process measures offer an attractive, additional approach for quality improvement. Focusing on and improving simpler process measures often fails to lead to improvements in meaningful outcomes. [47] [48] [49] [50] [51] Clinicians and health care systems can be more confident that a focus on improving linked process measures will translate to benefit for patients. 1 Such measures have the additional advantage that the action required of physicians or systems to improve quality (in this case, intensifying treatment) is implicit in the measure. They can be tailored to focus on optimal medication or clinical strategies for improving long-term outcomes.
Despite these attractive features, treatment intensification measures as constructed here would have limitations as external performance measures for health plans, physician groups, or individual physicians. Their measurement requires both risk factor and prescribing data, which are not readily available in less integrated delivery settings without electronic health records (EHRs). Conceivably, chart reviews could be adapted to obtain this added information, but standardized measurement would also require complex categorization of multiple drugs and combination medications into treatment classes, standard quantification of dosage increases, and measurement of risk-specific target levels. Each of these would require updating over time.
A second limitation is that the treatment intensification measures we constructed include only the minority of patients who are in poor control. As control improves, these denominators shrink. Using stricter definitions of control could enlarge denominators (ie, by including the larger numbers in "near control"), but we would be concerned that in a context of performance reporting and incentivization, more stringent cutpoints could lead to adverse effects of overmedication in patients who would stand to gain very little. 27, 28 However, in the setting of internal quality improvement, where there is less risk of perverse incentives, broader definitions of poor control could be examined. For example, patients who are in near control on 2 consecutive measures could be included, reasoning that nonpharmacologic efforts do not seem to be helping.
An additional limitation is that systems or groups with higher proportions already in control would not be recognized and could even be penalized by these measures if their smaller numbers of remaining poorly controlled patients were more resistant to intensification or more likely to have valid reasons not to intensify, such as intolerance to some medications or known nonadherence to current medications. Measures that combine proportions in control with proportions of remaining patients who received treatment intensification 25, 26 capture both aspects of clinical quality and were shown in this study to change performance rankings compared with simpler measures of percent in control.
Although the associations we observed were robust, the measures could be refined in several ways when data are available. Credit could be given for the small percentages of patients (3% of persons with diabetes or hyperlipidemia; 11% of those with hypertension) who returned to control without changes in pharmacotherapy by their next reading. 29 Patients who seemed to be nonadherent to present medications could be excluded before calculating intensification rates, as treatment intensification may be inappropriate for this group. 52 Credit could be given for small percentages (well below 10%) of hypertensive or hyperlipidemic patients already on maximal medical therapy 20, 29 and for persons with contraindications to some medication classes or with comorbidities that may make intensification inappropriate. 53 Measures could ultimately be refined to distinguish among treatment intensification choices, giving more credit for using recommended next steps in treatment intensification and withholding credit for intensifications that have been shown to be harmful. Lastly, prescriptions written rather than prescriptions filled may be a more direct measure of clinical performance, although data from Kaiser Permanente's EHR indicate that more than 95% of physicianordered prescriptions for new medications are filled at least once 54 and thus captured in prescription databases. These refinements could enhance the credibility of intensification measure with providers. A persistent limitation without obvious solution is the inability, in either EHR or prescription databases, to capture day-do-day intensifications of insulin therapy.
In conclusion, improvements in rates of treatment intensification for patients with poorly controlled hypertension, hyperlipidemia, or diabetes mellitus are directly related to improved population risk factor control. These measures deserve further consideration for use in improving clinical quality of care.
